僑雄國際(00381.HK)：擬收購生物醫藥科技公司部分股權
格隆匯 11 月 4日丨僑雄國際(00381.HK)宣佈，於2020年11月4日，公司全資附屬福建綠森農業科技有限公司與張莉就建議收購訂立收購框架協議。根據收購框架協議，買方將就收購目標公司部份已發行股本真誠商議協議的細節條款。
買賣雙方一致同意，可能收購事項的代價格將按照評估機構對目標公司的資產、潛力等進行評估的評估值作出調整並出具的公司淨資產值，以及轉讓股權的比例確定，買方及賣方同意該評估機構出具的報告。
據悉，目標公司為於2017年10月16日在中國註冊成立的有限公司。目標公司為一間從事生物醫藥科技領域的技術開發、技術服務、投資興辦醫藥項目及其他實業的公司。目標公司以生物技術協同創新中心平台來運營和打造集成果轉化、項目孵化、科學研究、人才交流等，在國內外有影響力的生物技術協同創新基地為目標；以為政府、企業提供一站式的科技服務為宗旨；以基因工程、細胞工程、蛋白質工程和診斷製劑、高分子材料、公共衞生等領域的應用性科學研究和產品開發為使命，充分發揮團隊科技資源優勢，粵港澳大灣區的科技創新優勢，聚集國內外傑出人才、孵化、培育優秀科技項目、加速產業落地。
目標公司研製開發的新型抗病毒藥物治療兒童呼吸道合胞病毒(RSV)感染已經積累了大量的循證學依據和客户基礎，因此預期該霧化吸入劑上市初期的3年，將集中在RSV領域獲得市場份額和利潤。
公告稱，中國生物製藥產業已經開始扮演着不可或缺的角色。主要原因一方面是由於中國生物技術的迅猛發展，另一方面是隨着國際醫藥產業轉移，眾多跨國生物醫藥公司開始將藥物研發及生產工作外包至中國。目前中國已有80多個地區(城市)已經着力建設醫藥科技園、生物園、藥谷。
集團發揮上市企業優勢及配合集團多元化發展的戰略，交易亦符合中國共產黨第十八屆中央委員會第五次全體會議通過的《中共中央關於制定國民經濟和社會發展第十三個五年規劃的建議》等，調整產業結構的政策。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
